• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    10/29/24 4:08:37 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email
    dva-20241029
    0000927066false00009270662024-10-292024-10-29

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     Form 8-K 

     CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of Report (date of earliest event reported): October 29, 2024  


     
    DAVITA INC.
    (Exact name of registrant as specified in its charter)
     

    DE1-1410651-0354549
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)(IRS Employer
    Identification No.)
     
    2000 16th Street
    Denver,CO80202
    (Address of principal executive offices including Zip Code)
     
    (720) 631-2100
    (Registrant’s telephone number, including area code)
     
    Not applicable
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class: Trading symbol(s):Name of each exchange on which registered:
    Common Stock, $0.001 par value DVANew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    ☐    Emerging growth company
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 2.02. Results of Operations and Financial Condition.
     
    On October 29, 2024, DaVita Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report.
     
    The information contained in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
     
    Item 9.01. Financial Statements and Exhibits.
     
    (d) Exhibits.
     
    Exhibit
    Number
    Description
    99.1
    Press Release dated October 29, 2024 announcing the registrant’s financial results for the quarter ended September 30, 2024.
    104.0Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.




    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    DAVITA INC.
    Date: October 29, 2024
    By:/s/    Christopher M. Berry
    Christopher M. Berry
    Chief Accounting Officer



    Get the next $DVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by DaVita Inc.

      DEFA14A - DAVITA INC. (0000927066) (Filer)

      4/24/25 5:20:43 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form DEF 14A filed by DaVita Inc.

      DEF 14A - DAVITA INC. (0000927066) (Filer)

      4/24/25 5:18:43 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 8-K filed by DaVita Inc.

      8-K - DAVITA INC. (0000927066) (Filer)

      4/14/25 6:54:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/13/24 5:02:42 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/9/22 3:43:35 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

      SC 13D/A - DAVITA INC. (0000927066) (Subject)

      8/4/21 4:02:59 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

      DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the

      4/30/25 11:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2025

      DENVER, March 6, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at the Barclays Global Healthcare Conference 2025 on Tuesday, March 11, 2025, at 9:00 a.m. EDT. To view the live webcast, visit the Barclays page and create a free registration. About DaVita Inc. DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares fo

      3/6/25 10:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities

      CHICAGO and DENVER, Feb. 27, 2025 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA), the national resource office for the 2,600+ YMCAs across the country, is excited to expand its collaboration with DaVita, a leading provider of comprehensive kidney care, to advance chronic disease education and prevention for individuals and their families who are either managing or at risk for chronic kidney disease (CKD). CKD disproportionately affects individuals with risk factors such as hypertension and diabetes. Following an investment from the DaVita Giving Foundation, Y-USA and DaVita will collaborate to further close the kidney health education gap, empower early risk detection and connect individuals

      2/27/25 9:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on DaVita with a new price target

      Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

      3/6/24 8:09:27 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita upgraded by UBS with a new price target

      UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

      8/7/23 7:20:56 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

      11/1/22 9:18:39 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Financials

    Live finance-specific insights

    See more
    • DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

      DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the

      4/30/25 11:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 4th Quarter 2024 Results

      DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe

      2/13/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

      DENVER, Jan. 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Thursday, February 13, 2025Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to

      1/30/25 11:55:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Rodriguez Javier was granted 18,822 shares, increasing direct ownership by 2% to 894,080 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      3/18/25 7:42:51 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Chief Compliance Officer Hearty James O was granted 1,185 shares and covered exercise/tax liability with 2,319 shares, decreasing direct ownership by 4% to 28,389 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      3/18/25 7:42:41 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Director Pullin Dennis W was granted 349 shares, increasing direct ownership by 57% to 961 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      3/18/25 7:42:31 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    See more
    • DaVita Appoints Jessica Hergenreter as Chief People Officer

      DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

      10/17/24 1:00:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

      DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

      9/13/24 8:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints New Chief Information Officer

      Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

      5/13/24 9:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care